New to The Street Announces its Five Corporate Interviews, Airing Episode 591 on the Fox Business Network, Tonight Monday, August 26, 2024, at 10:30 PM PT
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 26 2024
0mins
Source: Globenewswire
New to The Street Episode 591: The episode features interviews with executives from Acurx Pharmaceuticals, Iagon, GreenLite Ventures, and Sustainable Green Team, discussing advancements in biopharmaceuticals, decentralized data storage, digital sports betting, and sustainable solutions.
Cybersecurity Segment: Alain Ghiai of Sekur Private Data discusses recent hacks affecting major companies like AT&T and emphasizes the importance of secure communication services provided by Sekur, which uses military-grade encryption to protect user data.
Analyst Views on ACXP
Wall Street analysts forecast ACXP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACXP is 30.50 USD with a low forecast of 30.00 USD and a high forecast of 31.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.540
Low
30.00
Averages
30.50
High
31.00
Current: 2.540
Low
30.00
Averages
30.50
High
31.00
About ACXP
Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. It develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug-resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
